Evidence map›Paper›PMID 39282367›Full record

ArticlebioRxiv : the preprint server for biology2024

Dendritic cell effector mechanisms and tumor immune microenvironment infiltration define TLR8 modulation and PD-1 blockade.

Daniel A Ruiz-Torres, Jillian Wise, Brian Yinge Zhao, Joao Paulo Oliveira-Costa, Sara Cavallaro, Peter Sadow, Jacy Fang, Osman Yilmaz, Amar Patel, Christopher Loosbroock and 3 more

Registry-linked trialAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03906526 (A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03906526 phase1terminatednot on this map

A Phase 1b Multicenter Pre-Surgical Study to Evaluate Immune Biomarker Modulation in Response to Motolimod (VTX-2337) in Combination With Nivolumab in Subjects With Resectable Squamous Cell Carcinoma of the Head and Neck (SCCHN)

TypeinterventionalSponsorCelgeneRan2019 to 2022Enrolled15ConditionsCarcinoma, Squamous CellArmsVTX-2337, Nivolumab
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Daniel A Ruiz-TorresDepartment of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0001-6215-3369
Jillian WiseMassachusetts General Hospital Cancer Center, Boston, MA 02118, USA.
Brian Yinge ZhaoDepartment of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA 02115, USA.
Joao Paulo Oliveira-CostaMassachusetts General Hospital Cancer Center, Boston, MA 02118, USA.
Sara CavallaroMassachusetts General Hospital Cancer Center, Boston, MA 02118, USA.
Peter SadowDepartment of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA 02115, USA.
Jacy FangMassachusetts General Hospital Cancer Center, Boston, MA 02118, USA.
Osman YilmazDepartment of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Amar PatelBristol Myers Squibb, Seattle, WA 98109, USA.
Christopher LoosbroockBristol Myers Squibb, Seattle, WA 98109, USA.
Moshe Sade-FeldmanMassachusetts General Hospital Cancer Center, Boston, MA 02118, USA.
Daniel L FadenDepartment of Otolaryngology-Head and Neck Surgery, Harvard Medical School, Boston, MA 02115, USA.
Shannon L StottMassachusetts General Hospital Cancer Center, Boston, MA 02118, USA.

Funding

Benchmarking the Sensitivity and Specificity of the Herringbone Microfluidic Device for Rare Particle CaptureR01CA226871 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI NAHED, BRIAN VALA, STOTT, SHANNON L · 2018 to 2023
$2.3M
Microfluidic Isolation and Characterization of SARS-CoV-2 and Virus Related ExosomesU18TR003793 · NCATS · MASSACHUSETTS GENERAL HOSPITAL · PI BOLAND, GENEVIEVE MARIE, STOTT, SHANNON L · 2021 to 2022
$2.0M
Dissecting temporal and spatial dynamics of immunotherapy resistanceK23DE029811 · NIDCR · MASSACHUSETTS EYE AND EAR INFIRMARY · PI FADEN, DANIEL · 2021 to 2025
$869k
Circulating HPV DNA as a Prediagnostic Marker of Oropharyngeal CancerR21CA267152 · NCI · UNIVERSITY OF KENTUCKY · PI FADEN, DANIEL, KUHS, KRYSTLE A. · 2022 to 2023
$431k
Cell free HPV DNA detection in the diagnostic and surgical settingsR03DE030550 · NIDCR · MASSACHUSETTS EYE AND EAR INFIRMARY · PI FADEN, DANIEL · 2022 to 2023
$336k
NCATS NIH HHS U18 TR003793NCI NIH HHS R01 CA226871NCI NIH HHS R21 CA267152NIDCR NIH HHS K23 DE029811NIDCR NIH HHS R03 DE030550
6 · The paper itself

Abstract

The potent immunostimulatory effects of toll-like receptor 8 (TLR8) agonism in combination with PD-1 blockade have resulted in various preclinical investigations, yet the mechanism of action in humans remains unknown. To decipher the combinatory mode of action of TLR8 agonism and PD-1 blockade, we employed a unique, open-label, phase 1b pre-operative window of opportunity clinical trial (NCT03906526) in head and neck squamous cell carcinoma (HNSCC) patients. Matched pre- and post-treatment tumor biopsies from the same lesion were obtained. We used single-cell RNA sequencing and custom multiplex staining to leverage the unique advantage of same-lesion longitudinal sampling. Patients receiving dual TLR8 agonism and anti-PD-1 blockade exhibited marked upregulation of innate immune effector genes and cytokines, highlighted by increased

Indexed as

CancerCheckpoint blockadeDendritic cellsImmune ResponseImmunotherapy

Identifiers

PMID39282367
PMCPMC11398323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.